<!DOCTYPE html>
<html lang="fa">
 <meta content="text/html;charset=utf-8" http-equiv="content-type"/>
 <head>
  <title>
   Selection of an umbilical cord blood graft for hematopoietic cell transplantation
  </title>
  <link href="d/css/1.css" rel="stylesheet"/>
 </head>
 <body>
  <!-- Start Main Menu Area -->
  <br/>
  <br/>
  <br/>
  <br/>
  <div class="container">
   <div class="row">
   </div>
  </div>
  <section class="teacher-area ptb-10">
   <div class="container">
   </div>
   <section class="course-details-area ptb-60">
    <div class="container">
     <div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
      <h1 style="text-align:center">
       Selection of an umbilical cord blood graft for hematopoietic cell transplantation
      </h1>
      <div class="utdArticleSection utdStyle" id="topicContent">
       <div id="topicTitle">
        Selection of an umbilical cord blood graft for hematopoietic cell transplantation
       </div>
       <div class="authorSectionElem">
        <div class="authorsElementsLeft">
         <dl id="topicContributors">
          <dt>
           <span>
           </span>
           Author:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Nelson J Chao, MD
           </a>
          </dd>
          <dt>
           <span>
           </span>
           Section Editor:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Robert S Negrin, MD
           </a>
          </dd>
          <dt>
           <span>
           </span>
           Deputy Editor:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Alan G Rosmarin, MD
           </a>
          </dd>
         </dl>
        </div>
        <div class="authorsElementsRight">
         <div id="literatureReviewDate">
          <div class="litReviewSingleLine">
           <bdi>
            <span class="emphasis">
             Literature review current through:
            </span>
            Jan 2024.
           </bdi>
          </div>
          <div class="litReviewSingleLine">
           <bdi>
            <span class="emphasis">
             This topic last updated:
            </span>
            Apr 07, 2022.
           </bdi>
          </div>
         </div>
        </div>
       </div>
       <div id="topicWhatsNewContainer">
       </div>
       <div id="topicText">
        <p class="headingAnchor" id="H2564267">
         <span class="h1">
          INTRODUCTION
         </span>
         <span class="headingEndMark">
          —
         </span>
         Allogeneic hematopoietic cell transplantation (HCT) is an important and potentially curative treatment option for a variety of malignant and nonmalignant diseases. Human leukocyte antigen (HLA)-matched sibling donors (MSD) are the preferred graft source for allogeneic HCT, but most transplant candidates do not have a suitable HLA-identical MSD. For patients without a suitable MSD donor, identifying an unrelated donor through a national registry is a lengthy process that is not always successful, especially for individuals who are not of Northern European descent.
        </p>
        <p>
         Umbilical cord blood (UCB), the blood remaining in the umbilical cord and placenta following the birth of an infant, is an alternative graft source for allogeneic HCT. The relative ease of procurement, increased representation of ethnic minorities, and ability to use partially HLA-matched UCB units significantly expands the HCT donor pool. Use of lower-intensity conditioning regimens can facilitate engraftment of UCB and broadens the scope of patients who may benefit from allogeneic HCT, including older or less medically-fit patients. Approximately 35,000 UCB transplants were performed through 2020 and nearly three-quarters of a million UCB units are available worldwide through &gt;100 UCB banks [
         <a href="#rid1">
          1
         </a>
         ].
        </p>
        <p>
         The advantages and limitations of UCB and the selection of an umbilical cord blood graft are discussed in this topic.
        </p>
        <p>
         Use of UCB transplantation in adults using myeloablative and NMA regimens, and the collection, storage, and ethical issues regarding the use of UCB for HCT are discussed separately.
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         (See
         <a class="medical medical_review" href="/z/d/html/3531.html" rel="external">
          "Collection and storage of umbilical cord blood for hematopoietic cell transplantation"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         (See
         <a class="medical medical_review" href="/z/d/html/15767.html" rel="external">
          "Umbilical cord blood transplantation in adults using myeloablative and nonmyeloablative preparative regimens"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         (See
         <a class="medical medical_review" href="/z/d/html/3537.html" rel="external">
          "Hematopoietic cell transplantation (HCT): Sources of hematopoietic stem/progenitor cells"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         (See
         <a class="medical medical_review" href="/z/d/html/3535.html" rel="external">
          "Donor selection for hematopoietic cell transplantation"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H3294463950">
         <span class="h1">
          FEATURES OF UCB GRAFTS
         </span>
         <span class="headingEndMark">
          —
         </span>
         UCB is the blood remaining in the umbilical cord and placenta following the birth of an infant. UCB can provide the hematopoietic stem and progenitor cells that are needed for allogeneic HCT in patients who do not have a human leukocyte antigen (HLA)-matched related or unrelated donor.
        </p>
        <p>
         UCB transplantation (UCBT) from a related or unrelated donor is a well-accepted hematopoietic graft source in pediatric patients with hematologic malignancies, marrow failure, or metabolic syndromes. However, for allogeneic HCT in adults, relatively limited numbers of hematopoietic stem and progenitor cells in UCB units can impair engraftment and immune reconstitution, which are associated with unfavorable HCT outcomes.
        </p>
        <p class="headingAnchor" id="H3810806230">
         <span class="h2">
          Increased demand for UCBT
         </span>
         <span class="headingEndMark">
          —
         </span>
         There has been increased use of UCBT due to several factors, most of which address limitations encountered in the use of HLA-matched unrelated donor (MUD) graft. In some settings, increased use of haploidentical transplantation using post-transplant
         <a class="drug drug_general" data-topicid="9308" href="/z/d/drug information/9308.html" rel="external">
          cyclophosphamide
         </a>
         has reduced or reversed the trend toward greater use of UCBT.
        </p>
        <p>
         Demand for UCBT has increased due to:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Lack of suitable HLA-matched donors
         </strong>
         – Most patients do not have an HLA-identical relative, since each full sibling potential donor has only a 25 percent chance of being fully HLA-matched. A search for a MUD with ≥9/10 high-resolution HLA match is successful for approximately 80 percent for individuals of Northwestern European descent, but much lower for other ethnic groups [
         <a href="#rid2">
          2
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/3535.html" rel="external">
          "Donor selection for hematopoietic cell transplantation", section on 'Unrelated donors'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Donor attrition
         </strong>
         – Despite large lists of volunteer donors worldwide, a significant percentage of donors will no longer be available for donation when needed.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Time constraints
         </strong>
         – Identifying, typing, and harvesting an unrelated donor is cumbersome and lengthy process, with the median time interval between initiation of a search and the donation of marrow of about two to four months; a search can be expedited if necessary [
         <a href="#rid3">
          3
         </a>
         ]. A preliminary search usually provides insight into how likely it will be to identify a donor for an individual patient.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Graft-versus-host disease (GVHD)
         </strong>
         – HLA disparities when using bone marrow and peripheral blood graft sources are associated with increased GVHD [
         <a href="#rid4">
          4-6
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H2526197685">
         <span class="h2">
          Advantages
         </span>
         <span class="headingEndMark">
          —
         </span>
         Advantages for the use of UCB grafts include:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Expanded donor pool
         </strong>
         – Increased representation of ethnic minorities in the unrelated UCB banks and the ability to use partially HLA-matched UCB units significantly expands the donor pool [
         <a href="#rid2">
          2
         </a>
         ]. (See
         <a class="local">
          'HLA type'
         </a>
         below.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Ease of procurement and lack of donor attrition
         </strong>
         – UCB can be tested prior to storage for infections, blood and HLA-type, and cell dose, thereby making the specimen more rapidly available [
         <a href="#rid7">
          7
         </a>
         ]. Likewise, storage of UCB avoids the risk of donor attrition. Together, these characteristics result in a shorter time to UCBT, compared with unrelated bone marrow or peripheral blood grafts [
         <a href="#rid8">
          8
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/3531.html" rel="external">
          "Collection and storage of umbilical cord blood for hematopoietic cell transplantation"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Favorable outcomes
         </strong>
         – The incidence and severity of acute and chronic GVHD in recipients of HLA-disparate unrelated UCB grafts are lower than those associated with MUD or partially-matched related bone marrow grafts [
         <a href="#rid9">
          9
         </a>
         ]. UCBT is associated with similar overall survival (OS) and improved GVHD-free/relapse-free survival (GRFS), compared with matched related or unrelated grafts [
         <a href="#rid10">
          10-12
         </a>
         ]. (See
         <a class="local">
          'Outcomes'
         </a>
         below.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Safety for donors and recipients
         </strong>
         – UCB is relatively easy to collect after the delivery of a newborn and does not put the mother or newborn at risk. In addition, there is a reduced likelihood of transmitting infections (eg, cytomegalovirus) from the donor to the recipient.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          High proportion of engraftable cells
         </strong>
         – UCB units usually have fewer total nucleated cells (TNC) and CD34+ cells compared with a graft from bone marrow or peripheral blood. However, the proportion of engraftable cells (eg, primitive hematopoietic progenitor cells and multipotent colony-forming cells) in UCB is higher and the cells have greater higher self-renewal capacity, shorter cell cycle times, longer telomeres, and higher in vivo hematopoietic reconstitution capacity in animal models [
         <a href="#rid13">
          13-19
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H3893742406">
         <span class="h2">
          Disadvantages
         </span>
         <span class="headingEndMark">
          —
         </span>
         The main limitations of UCB as an HCT graft source are:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Increased risk of graft failure
         </strong>
         – UCB contains limited numbers of hematopoietic stem and progenitor cells; as a result, single UCB samples may contain an insufficient cell dose to reconstitute the bone marrow of a large child or adult. (See
         <a class="local">
          'Cell dose'
         </a>
         below.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Increased infections
         </strong>
         – UCBT is associated with more infectious complications, but not with more infection-related deaths, compared with unrelated donor bone marrow or peripheral blood grafts [
         <a href="#rid20">
          20
         </a>
         ]. The increase in infections is associated with slower neutrophil recovery and other effects on immune reconstitution, which may be related to use of antithymocyte globulin (ATG) [
         <a href="#rid21">
          21
         </a>
         ]. UCBT is associated with a longer median duration of neutropenia (30 versus 14 days), but not with an increase in infection-related deaths [
         <a href="#rid22">
          22
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/15767.html" rel="external">
          "Umbilical cord blood transplantation in adults using myeloablative and nonmyeloablative preparative regimens", section on 'Toxicity and transplant-related mortality'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Unavailability for additional donations
         </strong>
         – The donor is not available for subsequent donor lymphocyte infusions or other cell-based therapies.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Possible transplantation with a hematologic disorder
         </strong>
         – UCB samples are evaluated with a blood film and hemoglobinopathy screening prior to storage but, theoretically, there remains an increased risk of transmitting undetected hematologic diseases [
         <a href="#rid23">
          23
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Incidence of post-HCT autoimmune disorders
         </strong>
         – For patients who are transplanted for non-malignant disorders, the cumulative incidence of a new autoimmune disease after UCBT appears to be at least as high as other alternative donor sources. A registry study reported new autoimmune illnesses in 5 percent at one year and 7 percent at five years, with autoimmune hemolytic anemia, immune thrombocytopenia, and Evans syndrome being most common [
         <a href="#rid24">
          24
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H90744842">
         <span class="h1">
          UCB UNIT SELECTION
         </span>
         <span class="headingEndMark">
          —
         </span>
         The main criteria for selecting UCB unit(s) for transplantation are the human leukocyte antigen (HLA) haplotype and the total nucleated cell (TNC) dose per kilogram (kg) of recipient body weight.
        </p>
        <p class="headingAnchor" id="H3190558027">
         <span class="h2">
          Selection criteria
         </span>
         <span class="headingEndMark">
          —
         </span>
         We consider the following criteria for choosing a UCB graft:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Closest HLA match
         </strong>
         – ≥4/6 HLA match (HLA-A, -B, -DRB1) or ≥4/8 match (HLA-A, -B, -C, -DRB1) (see
         <a class="local">
          'HLA type'
         </a>
         below)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Cell dose
         </strong>
         – Either of the following:
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         ≥3 x
         <sup>
         </sup>
         10
         <sup>
          7
         </sup>
         TNC/kg of recipient body weight
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         or
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         ≥2 x
         <sup>
         </sup>
         10
         <sup>
          5
         </sup>
         CD34+ cells/kg recipient body weight (see
         <a class="local">
          'Cell dose'
         </a>
         below)
        </p>
        <p>
        </p>
        <p>
         Potential UCB units with the greatest HLA-match that have an acceptable TNC count should be chosen. Cryopreservation of UCB cells does not require discarding any type of cells prior to freezing and the cells should not be washed or otherwise handled after thawing (to avoid loss of stem and progenitor cells) [
         <a href="#rid25">
          25
         </a>
         ].
        </p>
        <p>
         When no single UCB unit satisfies both selection criteria, options include use of two UCB units (double UCB transplantation; dUCBT), ex vivo expansion, or alterations in the conditioning or immunosuppressive regimens. For dUCBT, the two units should have a combined dose of ≥3 x 10
         <sup>
          7
         </sup>
         TNC/kg. If possible, there should be ≤1 HLA difference
         <sup>
         </sup>
         between the UCB units and the patient. In patients without a malignant disease, the cell doses should be higher or the HLA incompatibility lower. (See
         <a class="local">
          'Strategies for inadequate cell dose'
         </a>
         below.)
        </p>
        <p>
         A "backup graft" should be available in case of unexpected problems when the selected UCB unit thaws or if it fails to engraft [
         <a href="#rid26">
          26
         </a>
         ]. The backup unit is reserved at the UCB bank until the patient has engrafted; after engraftment, the reservation is cancelled. Collection of autologous hematopoietic progenitor cells as a backup graft for patients at higher risk of graft failure does not appear to be necessary, especially in patients with a 6 of 6 HLA-match who are undergoing myeloablative UCB transplantation [
         <a href="#rid27">
          27
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H61604493">
         <span class="h2">
          HLA type
         </span>
         <span class="headingEndMark">
          —
         </span>
         Matching donor and recipient for HLA class I (-A, -B, and -C) and class II (-DRB1 and -DQ) haplotypes is a key part of successful UCB transplantation (UCBT). Units with the greatest similarity in HLA haplotype to the recipient and sufficient cell dose should be selected. However, compared with other alternative donor sources, such as bone marrow (BM) or peripheral blood (PB) grafts from unrelated donors, UCBT can be performed using less-stringently matched grafts.
        </p>
        <p>
         Most UCB banks evaluate UCB samples using serologic testing for HLA-A and HLA-B and molecular typing for HLA-DRB1. Using this method, units that are matched at 4, 5, or 6 of 6 HLA alleles are acceptable sources; UCB units with HLA-matches ≤3/6 are not acceptable because such units are associated with high treatment related mortality (TRM) and low rates of disease-free survival (DFS) [
         <a href="#rid28">
          28,29
         </a>
         ]. When available, additional matching for HLA-C improves patient outcomes. This testing approach differs from that used for unrelated donor BM or PB graft matching, in which molecular typing of 10 HLA alleles is preferred and acceptable donors are generally limited to ≤1 HLA-mismatch [
         <a href="#rid30">
          30
         </a>
         ].
        </p>
        <p>
         Once a UCB unit has been selected for transplantation, HLA-typing must be confirmed on an attached or contiguous segment of the product. The importance of confirmatory HLA-typing was illustrated by a study that reported that 2 of 871 UCB units (0.2 percent) sent to a single medical center for HCT were mislabeled and potentially would have been transplanted incorrectly [
         <a href="#rid31">
          31
         </a>
         ].
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          HLA-matching
         </strong>
         – Although UCBT is associated with higher TRM, rates of acute and chronic graft-versus-host disease (GVHD) are generally lower than with BM or PB grafts for HCT. UCB units with ≥4 of 6 HLA match produce outcomes that are at least as good as an 8 of 8 HLA-matched BM for HCT in children with a malignancy. (See
         <a class="local">
          'UCB versus matched sibling donor'
         </a>
         below.)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         The degree of HLA mismatch can affect UCBT outcomes. In a retrospective analysis of 803 patients (up to age 62 years) with leukemia or a myelodysplastic syndrome (MDS), compared with patients matched at 8 HLA loci (ie, HLA-A, -B, -C, -DRB1), TRM was increased for patients mismatched at two HLA loci (ie, 6 of 8 HLA match; hazard ratio [HR] 3.27 [95% CI 1.42-7.54]), three loci (HR 3.34 [95% CI 1.4-7.71]), or four loci (HR 3.51 [95% CI 1.44-8.58]) loci [
         <a href="#rid32">
          32
         </a>
         ]. Patients mismatched for HLA-C, also had higher TRM, whether they were matched at HLA-A, -B, and -DRB1 (HR 3.97, 95% CI 1.27-12.40) or had a single mismatch at HLA-A, -B, or -DRB1 (HR 1.70 [95% CI 1.06-2.74]). Similarly, mismatching for HLA-DRB1 increased TRM among patients mismatched at a single HLA-A, -B, or -C locus.
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         In a retrospective study of children with acute leukemia who underwent myeloablative conditioning (MAC), outcomes were compared between 503 children given an unrelated mismatched
         <sup>
         </sup>
         UCBT versus 282 children who received a matched unrelated donor (MUD) BM graft [
         <a href="#rid33">
          33
         </a>
         ]. HLA-mismatched BM recipients had
         <sup>
         </sup>
         more acute and chronic GVHD, without improving leukemia-free
         <sup>
         </sup>
         survival (LFS). Five-year LFS was higher in children who received 6 of 6 HLA-matched (HLA-A,-B,-DRB1) UCBT than in children who received 8 of 8 (HLA-A,-B,-C,-DRB1) matched BM transplants (60 versus 38 percent). There was a trend toward decreasing five-year LFS with increasing UCB HLA-disparity.
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Similar results were also reported in other studies [
         <a href="#rid34">
          34-39
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Other matching
         </strong>
         – The importance of other matching of donor and recipient is less well-defined:
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          KIR gene
         </strong>
         <strong>
          matching
         </strong>
         – The killer-cell immunoglobulin-like receptor (KIR) gene encodes natural killer cell immunoglobulin-like receptors that recognize epitopes of HLA-A, HLA-B, and HLA-C (so-called KIR ligands) and may impact outcomes after UCBT [
         <a href="#rid40">
          40
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/3535.html" rel="external">
          "Donor selection for hematopoietic cell transplantation", section on 'KIR gene haplotype'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Recipient HLA antibodies
         </strong>
         – HLA-mismatched units that contain HLA determinants for which the recipient has pre-formed HLA antibodies should be avoided [
         <a href="#rid41">
          41
         </a>
         ]. If donor-specific antibodies are detected, the unit should not be used, or the recipient should be treated to remove the antibodies. (See
         <a class="medical medical_review" href="/z/d/html/3535.html" rel="external">
          "Donor selection for hematopoietic cell transplantation", section on 'Donor-specific HLA antibodies'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H61604500">
         <span class="h2">
          Cell dose
         </span>
         <span class="headingEndMark">
          —
         </span>
         Cell dose can be assessed according to either TNC/kg recipient body weight or CD34+ cells/kg recipient body weight. Clinically important outcomes, including the incidence of graft failure and speed of bone marrow recovery, correlate with TNC dose/kg [
         <a href="#rid28">
          28,42
         </a>
         ]. Higher doses are required for engraftment of UCB units with greater HLA-disparity. However, the ideal cell dose for UCBT is not well-defined and progenitor cell measurements are not standardized among UCB banks.
        </p>
        <p>
         In general, units should have ≥3 x 10
         <sup>
          7
         </sup>
         nucleated cells/kg or ≥2 x 10
         <sup>
          5
         </sup>
         CD34+ cells/kg. The risk of graft rejection is higher in patients who undergo UCBT for non-malignant diseases, and a dose of ≥3.5 x 10
         <sup>
          7
         </sup>
         nucleated cells/kg has been suggested, based on poor survival if lower TNC doses were administered [
         <a href="#rid38">
          38
         </a>
         ].
        </p>
        <p>
         Actual recipient body weight should be used, rather than ideal or adjusted body weight. All UCB units should have a TNC dose measured prior to cryopreservation. Although less commonly provided, a measure of CD34+ cells [
         <a href="#rid43">
          43
         </a>
         ] can be used; colony forming units (CFUs) are now rarely used [
         <a href="#rid44">
          44-46
         </a>
         ]. Successful engraftment generally requires ≥3 x 10
         <sup>
          7
         </sup>
         TNC/kg or ≥2 x 10
         <sup>
          5
         </sup>
         CD34+ cells/kg [
         <a href="#rid29">
          29,39
         </a>
         ] and, if two UCB units are used, each individual unit should have ≥2.0 x 10
         <sup>
          7
         </sup>
         TNC/kg [
         <a href="#rid26">
          26
         </a>
         ]. (See
         <a class="local">
          'Double UCBT'
         </a>
         below.)
        </p>
        <p>
         Retrospective studies have illustrated the importance of cell dose on outcomes with UCBT [
         <a href="#rid33">
          33,39,43,47,48
         </a>
         ].
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         In an analysis of 1568 patients who received single-unit MAC UCBT for leukemia or MDS, those who received &lt;3 x 10
         <sup>
          7
         </sup>
         TNC/kg had 15 to 20 percent higher non-relapse mortality (NRM) than those who received TNC ≥3 x 10
         <sup>
          7
         </sup>
         per kg [
         <a href="#rid39">
          39
         </a>
         ]. Selection of a unit with TNC &gt;5 x 10
         <sup>
          7
         </sup>
         per kg did not further decrease NRM for those with ≥5 of 8 HLA match; however, TNC &gt;5 x 10
         <sup>
          7
         </sup>
         per kg was associated with decreased NRM among those with a 4 of 8 HLA match.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         TRM increased with decreasing TNC dose and increasing HLA-disparity in analysis of 1061 patients who received a single-unit UCBT with MAC for leukemia or MDS [
         <a href="#rid29">
          29
         </a>
         ]. The highest rates of TRM were seen for patients who received a unit with TNC &lt;2.5 x
         <sup>
         </sup>
         10
         <sup>
          7
         </sup>
         /kg, regardless of HLA-disparity; conversely, TRM was lowest for 6 of 6 HLA-matched units regardless of TNC dose. TRM rates were similar for patients who received either a 5 of 6 HLA-matched unit with a TNC 2.5-5 x
         <sup>
         </sup>
         10
         <sup>
          7
         </sup>
         /kg or a 4 of 6 HLA-matched unit with a TNC of ≥5 x
         <sup>
         </sup>
         10
         <sup>
          7
         </sup>
         / kg. Higher TRM was seen for patients who received a 4 of 6 HLA-matched unit with a TNC between 2.5-5 x 10
         <sup>
          7
         </sup>
         per kg.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Higher TRM
         <sup>
         </sup>
         was
         <sup>
         </sup>
         reported for children who received TNC &lt;3 x 10
         <sup>
          7
         </sup>
         /kg
         <sup>
         </sup>
         with one HLA disparity and for children given a two HLA-disparate
         <sup>
         </sup>
         UCBT (independent of cell dose) in an analysis of UCBT in 503 children with acute leukemia [
         <a href="#rid33">
          33
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H370342233">
         <span class="h2">
          Other factors
         </span>
         <span class="headingEndMark">
          —
         </span>
         Other factors that may influence UCB unit selection include the following:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Bank of origin
         </strong>
         – UCB banks that are accredited by NetCord-FACT are preferred. UCB quality, reliability of unit information, turnaround time, fees, and communication may vary from bank to bank [
         <a href="#rid49">
          49
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          RBC content
         </strong>
         – UCB units are typically processed prior to freezing to remove red blood cells (RBC), plasma, or both. UCB samples that have not had RBC-depletion should be washed prior to administration to remove RBC debris and free hemoglobin that may cause significant infusion reactions. Unprocessed UCB units typically contain more
         <a class="drug drug_general" data-topicid="8898" href="/z/d/drug information/8898.html" rel="external">
          dimethyl sulfoxide
         </a>
         (DMSO).
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Infectious disease monitoring
         </strong>
         – Donor mothers should be screened for hepatitis B, HIV, syphilis, HTLV-1, HTLV-2, and cytomegalovirus [
         <a href="#rid26">
          26
         </a>
         ]. UCB units should be analyzed for sterility with bacterial and fungal cultures. In addition, more recently collected units are also tested for West Nile virus and Chagas disease.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Hematologic disease screening
         </strong>
         – Prior to storage, UCB should be screened for hematologic diseases with a blood film and hemoglobinopathy screening. Units with normal hemoglobin analysis and those with hemoglobin F are acceptable. If no other UCB units are suitable, use of UCB units that are heterozygous for either sickle cell disease (ie, sickle cell trait) or thalassemia (but not both) may be considered [
         <a href="#rid26">
          26
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Age of stored unit
         </strong>
         – There is no accepted "shelf life" for UCB units and outcomes using older units appear to be equal to those with shorter storage duration. (See
         <a class="medical medical_review" href="/z/d/html/3531.html" rel="external">
          "Collection and storage of umbilical cord blood for hematopoietic cell transplantation", section on 'Shelf-life of units'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H3212823015">
         <span class="h1">
          STRATEGIES FOR INADEQUATE CELL DOSE
         </span>
         <span class="headingEndMark">
          —
         </span>
         Single UCB units often have insufficient cell dose for reconstitution of the bone marrow of a large child or adult (eg, &gt;70 kg). Several strategies can be employed when the cell dose is insufficient for UCB transplantation (UCBT), but the preferred approach varies among institutions.
        </p>
        <p class="headingAnchor" id="H126059187">
         <span class="h2">
          Double UCBT
         </span>
         <span class="headingEndMark">
          —
         </span>
         Double UCBT (dUCBT; ie, infusion of two UCB units) is acceptable for recipients without a single UCB unit of adequate cell dose, but single-unit UCBT (sUCBT) is generally preferred. Although graft acquisition costs and graft-versus-host disease (GVHD) may be increased with dUCBT, more adult patients receive dUCBT than sUCBT [
         <a href="#rid50">
          50
         </a>
         ].
        </p>
        <p>
         Compared with adequately-dosed sUCBT, patients receiving dUCBT generally have similar overall survival (OS), higher rates of grade ≥2 acute GVHD (aGVHD), and modestly delayed engraftment, but may have fewer relapses [
         <a href="#rid51">
          51-53
         </a>
         ].
        </p>
        <p>
         When two UCB units are infused, there may be a transient chimerism (ie, hematopoietic cells from both grafts are present), followed by the sustained dominance of one of the units by day 100 [
         <a href="#rid54">
          54
         </a>
         ]. A prolonged state of mixed chimerism is more common in patients receiving less intensive preparative regimens [
         <a href="#rid55">
          55
         </a>
         ].
        </p>
        <p>
         Outcomes using dUCBT include:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         A phase 3 trial randomly assigned of 224 children (&lt;21 years) undergoing myeloablative conditioning (MAC) HCT to either sUCBT versus dUCBT [
         <a href="#rid53">
          53
         </a>
         ]. After a median follow-up of 27 months, both trial arms achieved similar one-year OS (65 percent for dUCBT versus 73 percent for sUCBT) and comparable disease-free survival (DFS), time to neutrophil recovery, infections, and grade ≥2 aGVHD. However, sUCBT was associated with improved platelet recovery, less grade ≥3 aGVHD (13 versus 23 percent), and a lower incidence of extensive chronic GVHD (9 versus 15 percent).
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Another phase 3 trial reported that dUCBT did not decrease transplant strategy failure (a composite endpoint of transplant-related mortality [TRM], engraftment failure, and autologous recovery), but was associated with higher rates of GVHD and delayed relapses [
         <a href="#rid56">
          56
         </a>
         ]. A follow-up analysis reported that dUCBT may enhance the graft-versus-leukemia effect and survival in patients with measurable residual disease [
         <a href="#rid57">
          57
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         A retrospective study reported that dUCBT was associated with better outcomes and was more cost-effective for adults with acute leukemia in first CR; however, unlike other studies, this report did not require TNC ≥2.5 x 10
         <sup>
          7
         </sup>
         TNC/kg for patients undergoing sUCBT [
         <a href="#rid58">
          58
         </a>
         ]. Compared with sUCBT (61 patients), dUCBT (73 patients) was associated with superior OS (62 versus 42 percent) and two-year leukemia-free survival (LFS; 53 versus 33 percent), but more grade ≥2 aGVHD (52 versus 34 percent); there was no difference in grade ≥3 aGVHD. Neutrophil engraftment occurred in 78 versus 69 percent for dUCBT and sUCBT, respectively, and there was no difference in non-relapse mortality (NRM). Another study also reported fewer relapses in association with dUCBT [
         <a href="#rid59">
          59
         </a>
         ] and a retrospective review of 97 patients (age ≥14 years, ≥50kg) reported that dUCBT group was associated with lower five-year TRM (54 versus 33 percent) and GVHD-free/relapse-free survival [
         <a href="#rid60">
          60
         </a>
         ].
        </p>
        <p>
        </p>
        <p>
         Some experts suggest that UCB units should share ≥3 of 6 human leukocyte antigen (HLA)-match with one another, while others do not place limits on the unit-to-unit match. Retrospective analyses have not demonstrated a relationship between unit-to-unit HLA match and the likelihood of sustained donor engraftment [
         <a href="#rid26">
          26,61
         </a>
         ]. The dominant graft cannot be predicted based upon the respective doses, level of CD3+ cells, cell viability, degree of HLA-match, ABO group, sex of donor, or order and route of infusion [
         <a href="#rid20">
          20
         </a>
         ]. A single-institution series of 84 recipients of dUCBT reported that the unit with the higher dose was more likely to become dominant and that a high level of unit-to-unit HLA match was associated with an increased likelihood of engrafting both UCB units [
         <a href="#rid61">
          61
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H996232678">
         <span class="h2">
          Improving cell dose
         </span>
         <span class="headingEndMark">
          —
         </span>
         Ex vivo expansion of cell dose and supplementation with a limited number of mobilized peripheral blood stem and progenitor cells (PBSPC) from an HLA-unrestricted third party donor or haploidentical donor (ie, dual transplants) have been used to enhance the cell dose for UCBT.
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Ex vivo expansion
         </strong>
         – Ex vivo expansion of UCB stem and progenitor cells prior to transplantation may shorten the period of hematopoietic recovery and hasten immune reconstitution associated with UCBT.
         <a class="drug drug_general" data-topicid="9696" href="/z/d/drug information/9696.html" rel="external">
          Nicotinamide
         </a>
         has been shown to expand committed and long-term repopulating stem and progenitor cells and increase bone marrow homing and engraftment potential [
         <a href="#rid62">
          62-64
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         In a phase 3 trial, a nicotinamide-expanded cell product from a single banked UCB specimen achieved faster engraftment and reduced infections compared with standard UCB product; there was no difference in GVHD or overall survival [
         <a href="#rid65">
          65
         </a>
         ]. Patients undergoing myeloablative conditioning (125 patients, 13 to 65 years) were randomly assigned to the ex vivo expanded product (
         <a class="drug drug_general" data-topicid="141800" href="/z/d/drug information/141800.html" rel="external">
          Omidubicel
         </a>
         ) versus standard single or double UCB grafts. The expanded product achieved significantly faster median time to neutrophil engraftment (10 versus 20 days) and platelet engraftment (37 versus 50 days), with less primary graft failure (2 versus 10 percent). There was no significant difference in the incidence of acute GVHD or chronic GVHD, non-relapse mortality, or relapse. Patients receiving the expanded product had fewer grade ≥3 bacterial/fungal infections (37 versus 57 percent), were discharged sooner (median 27 versus 35 days) and spent more of the first 100 days alive and out-of-hospital (61 versus 48 days). Another study also reported that patients who received ex vivo nicotinamide-expanded UCB grafts experienced faster engraftment and fewer infections compared with historical controls [
         <a href="#rid66">
          66
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Other methods for ex vivo expansion have also been explored [
         <a href="#rid67">
          67-72
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Dual transplant
         </strong>
         – Infusion of mobilized PBSPCs from a nonmaternal HLA-haploidentical relative may facilitate durable engraftment of single UCB units in adults [
         <a href="#rid73">
          73,74
         </a>
         ]. In one study, 45 patients received a reduced intensity conditioning regimen followed by infusion of a matched UCB unit and HLA haploidentical PBSPCs [
         <a href="#rid74">
          74
         </a>
         ]. Most patients demonstrated early transient haploidentical engraftment followed by permanent UCB engraftment with or without evidence of minor host- or haploidentical-derived hematopoiesis. The median times to neutrophil and platelet engraftment were 11 and 19 days, respectively. The cumulative incidences of acute and chronic GVHD were 25 and 6 percent at one year.
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H1593429405">
         <span class="h1">
          OUTCOMES
         </span>
         <span class="headingEndMark">
          —
         </span>
         UCB transplantation (UCBT) is associated with excellent overall survival (OS), a low incidence of chronic graft-versus-host disease (GVHD), and favorable GVHD-free/relapse-free survival (GRFS) compared with HCT using matched-related or unrelated grafts. However, graft failure or delayed engraftment, increased transplant-related mortality (TRM), and more infectious risk remain important challenges.
        </p>
        <p class="headingAnchor" id="H3998282424">
         <span class="h2">
          UCB versus matched sibling donor
         </span>
         <span class="headingEndMark">
          —
         </span>
         UCBT is associated with more GVHD, but lower rates of relapse and better GRFS compared with human leukocyte antigen (HLA)-matched sibling donor (MSD) HCT.
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Unrelated UCBT was compared with MSD grafts for HCT using a myeloablative conditioning (MAC) regimen in children and adults with acute myeloid leukemia (AML) [
         <a href="#rid10">
          10
         </a>
         ]. Compared with 55 patients who underwent MSD HCT, 107 patients who received a single unit UCBT had no differences in TRM, grade ≥2 acute GVHD (aGVHD), or grade ≥3 acute aGVHD. UCBT was associated with a lower incidence of relapse, better GRFS, and a lower incidence of chronic GVHD (cGVHD) and extensive cGVHD.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         A retrospective study compared outcomes among 190 adult patients undergoing double-unit UCBT (dUCBT) versus 123 adults receiving MSD HCT [
         <a href="#rid11">
          11
         </a>
         ]. OS was comparable between cohorts, but GRFS was superior for UCBT patients, primarily due to decreased moderate to severe cGVHD.
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H3235579703">
         <span class="h2">
          UCB versus matched unrelated or mismatched unrelated donor
         </span>
         <span class="headingEndMark">
          —
         </span>
         Leukemia-free survival (LFS) after dUCBT transplantation is comparable with that after MSD and matched unrelated donor (MUD) HCT.
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         In patients with measurable residual disease (MRD) with AML or myelodysplastic syndrome (MDS), UCBT was associated with a lower rate of relapse than MUD and mismatched unrelated donor (mMUD) HCT in a retrospective analysis of 582 patients [
         <a href="#rid75">
          75
         </a>
         ]. The relative risks of death and relapse varied according to MRD status prior to HCT; however, among patients with MRD, the rate of OS with UCBT was at least as favorable as MUD HCT and was higher than OS after mMUD HCT.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         A multicenter retrospective study compared outcomes with acute leukemias after UCBT (79 patients) versus HCT using unrelated peripheral blood stem and progenitor cell transplantation (PBSPC; 96 patients) [
         <a href="#rid12">
          12
         </a>
         ]. aGVHD, TRM, OS, and LFS were similar between groups, but UCBT recipients had higher three-year GRFS and performance status, less moderate/severe cGVHD, and lower incidence of Epstein-Barr virus (EBV) viremia and post-transplantation lymphoproliferative disease (PTLD).
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Another retrospective study reported outcomes after MAC HCT for hematologic malignancies using MSD (204 patients), MUD (152 patients), one antigen-mismatched mMUD (52 patients), or ≥4 of 6 HLA-matched dUCB (128 patients) [
         <a href="#rid76">
          76
         </a>
         ]. Five-year LFS was similar for each donor type (ranging from 33 to 51 percent), but compared with other donor sources, dUCB was associated with a lower risk of relapse (15 versus 35 to 43 percent) yet higher rates of non-relapse mortality (NRM; 34 versus 14 to 24 percent).
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H2494821337">
         <span class="h2">
          UCB versus haploidentical HCT
         </span>
         <span class="headingEndMark">
          —
         </span>
         UCBT is associated with similar OS compared with HCT using a haploidentical graft (eg, from a parent or child), but rates of NRM and relapse differ.
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         A multicenter phase 3 trial (BMT CTN 1101) reported no difference in platelet recovery, grade ≥2 aGVHD and grade ≥3 aGVHD, cGVHD, or rate of relapse [
         <a href="#rid77">
          77
         </a>
         ]. There was no difference in two-year progression-free survival (PFS) between the donor sources, but UCBT recipients had delayed neutrophil recovery, increased TRM, and decreased OS.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         A study compared outcomes of 50 patients who underwent reduced intensity conditioning (RIC) dUCBT versus 50 patients who received RIC haploidentical donor bone marrow transplant for leukemia or lymphoma [
         <a href="#rid78">
          78
         </a>
         ]. Rates of OS and PFS were similar for both groups; UCBT was associated with 54 percent one-year OS and 46 percent one-year PFS, while the corresponding rates for haploidentical HCT were 62 and 48 percent. For dUCBT, one-year NRM was 24 percent, compared with 7 percent with haploidentical HCT, and one-year relapse rates were 31 and 45 percent, respectively.
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H3137438372">
         <span class="h1">
          UCB RESOURCES
         </span>
         <span class="headingEndMark">
          —
         </span>
         UCB banks have been established for related and unrelated UCB transplantation (UCBT), with several hundred thousand units available in &gt;100 cord blood banks worldwide (
         <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fwmda.info%2F&amp;token=RqEnnJm48SmpMklttm3edXKppckqGfx978ja7I4DjEw%3D&amp;TOPIC_ID=16563" target="_blank">
          wmda.info
         </a>
         ) [
         <a href="#rid23">
          23,79,80
         </a>
         ]. Procedures and quality standards for the safe collection, processing, testing, storage, selection, exchange, and clinical use of UCB are provided by NetCord-Foundation for the Accreditation of Cellular Therapy (www.factwebsite.org). (See
         <a class="medical medical_review" href="/z/d/html/3531.html" rel="external">
          "Collection and storage of umbilical cord blood for hematopoietic cell transplantation"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H61605643">
         <span class="h1">
          SUMMARY
         </span>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Umbilical cord blood (UCB)
         </strong>
         – UCB is the blood remaining in the umbilical cord and placenta following the birth of an infant. UCB has emerged as an alternative graft source for allogeneic hematopoietic cell transplantation (HCT) in children and adults.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Advantages and disadvantages
         </strong>
         – Compared with other alternative donor sources, UCB transplantation (UCBT) can expand the donor pool, facilitate graft procurement, lacks donor attrition, and is associated with decreased graft-versus-host disease (GVHD). However, UCBT is associated with an increased risk for graft failure, delayed immune reconstitution, and unavailability of the donor for additional donations (ie, donor lymphocyte infusions). (See
         <a class="local">
          'Features of UCB grafts'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          UCB unit selection
         </strong>
         – The main criteria for selecting UCB unit(s) for transplantation are the human leukocyte antigen (HLA) haplotype and the cryopreserved total nucleated cell (TNC) dose per kilogram recipient body weight.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         We select UCB unit(s) according to the following criteria:
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Closest HLA match
         </strong>
         – ≥4/6 HLA match (HLA-A, -B, -DRB1) or ≥4/8 match (HLA-A, -B, -C, -DRB1) (see
         <a class="local">
          'HLA type'
         </a>
         above)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Cell dose
         </strong>
         – ≥3 x 10
         <sup>
          7
         </sup>
         TNC/kg or ≥2 x 10
         <sup>
          5
         </sup>
         CD34+ cells/kg (see
         <a class="local">
          'Cell dose'
         </a>
         above)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Other factors
         </strong>
         – The UCB bank of origin, red blood cell content, age of the stored unit, and screening for infectious and hematologic diseases may also influence selection. (See
         <a class="local">
          'Other factors'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Inadequate cell dose
         </strong>
         – If single UCB units have insufficient cell dose for a large child or adult (eg, &gt;70 kg), the preferred approach varies among institutions, but options include:
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Double umbilical cord transfusion. (See
         <a class="local">
          'Double UCBT'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Ex vivo expansion or supplementation with mobilized peripheral blood stem and progenitor cells (PBSPCs) from a nonmaternal HLA-haploidentical relative. (See
         <a class="local">
          'Improving cell dose'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p>
        </p>
       </div>
       <div class="headingAnchor" id="references">
        <ol id="reference">
         <li>
          <a class="nounderline abstract_t">
           Zhu X, Tang B, Sun Z. Umbilical cord blood transplantation: Still growing and improving. Stem Cells Transl Med 2021; 10 Suppl 2:S62.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Querol S, Rubinstein P, Marsh SG, et al. Cord blood banking: 'providing cord blood banking for a nation'. Br J Haematol 2009; 147:227.
          </a>
         </li>
         <li class="breakAll">
          Howe CW, Radde-Stepaniak T. Hematopoietic cell donor registries. In: Hematopoietic Cell Transplantation, 2nd ed, Thomas ED, Blume KG, Forman SJ (Eds), Blackwell Science, Malden 1999. p.503.
         </li>
         <li>
          <a class="nounderline abstract_t">
           Barker JN, Wagner JE. Umbilical cord blood transplantation: current state of the art. Curr Opin Oncol 2002; 14:160.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kernan NA, Bartsch G, Ash RC, et al. Analysis of 462 transplantations from unrelated donors facilitated by the National Marrow Donor Program. N Engl J Med 1993; 328:593.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Beatty PG, Clift RA, Mickelson EM, et al. Marrow transplantation from related donors other than HLA-identical siblings. N Engl J Med 1985; 313:765.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Gluckman E, Rocha V, Chevret S. Results of unrelated umbilical cord blood hematopoietic stem cell transplant. Transfus Clin Biol 2001; 8:146.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Barker JN, Krepski TP, DeFor TE, et al. Searching for unrelated donor hematopoietic stem cells: availability and speed of umbilical cord blood versus bone marrow. Biol Blood Marrow Transplant 2002; 8:257.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Rocha V, Wagner JE Jr, Sobocinski KA, et al. Graft-versus-host disease in children who have received a cord-blood or bone marrow transplant from an HLA-identical sibling. Eurocord and International Bone Marrow Transplant Registry Working Committee on Alternative Donor and Stem Cell Sources. N Engl J Med 2000; 342:1846.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Zheng CC, Zhu XY, Tang BL, et al. Clinical separation of cGvHD and GvL and better GvHD-free/relapse-free survival (GRFS) after unrelated cord blood transplantation for AML. Bone Marrow Transplant 2017; 52:88.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Sharma P, Purev E, Haverkos B, et al. Adult cord blood transplant results in comparable overall survival and improved GRFS vs matched related transplant. Blood Adv 2020; 4:2227.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Tong J, Xuan L, Sun Y, et al. Umbilical Cord Blood Transplantation without Antithymocyte Globulin Results in Similar Survival but Better Quality of Life Compared with Unrelated Peripheral Blood Stem Cell Transplantation for the Treatment of Acute Leukemia-A Retrospective Study in China. Biol Blood Marrow Transplant 2017; 23:1541.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Brown JA, Boussiotis VA. Umbilical cord blood transplantation: basic biology and clinical challenges to immune reconstitution. Clin Immunol 2008; 127:286.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           da Silva CL, Gonçalves R, Porada CD, et al. Differences amid bone marrow and cord blood hematopoietic stem/progenitor cell division kinetics. J Cell Physiol 2009; 220:102.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Theunissen K, Verfaillie CM. A multifactorial analysis of umbilical cord blood, adult bone marrow and mobilized peripheral blood progenitors using the improved ML-IC assay. Exp Hematol 2005; 33:165.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bock TA, Orlic D, Dunbar CE, et al. Improved engraftment of human hematopoietic cells in severe combined immunodeficient (SCID) mice carrying human cytokine transgenes. J Exp Med 1995; 182:2037.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Vormoor J, Lapidot T, Pflumio F, et al. Immature human cord blood progenitors engraft and proliferate to high levels in severe combined immunodeficient mice. Blood 1994; 83:2489.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Mayani H, Wagner JE, Broxmeyer HE. Cord blood research, banking, and transplantation: achievements, challenges, and perspectives. Bone Marrow Transplant 2020; 55:48.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Mayani H. Biological differences between neonatal and adult human hematopoietic stem/progenitor cells. Stem Cells Dev 2010; 19:285.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Delaney C, Gutman JA, Appelbaum FR. Cord blood transplantation for haematological malignancies: conditioning regimens, double cord transplant and infectious complications. Br J Haematol 2009; 147:207.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Admiraal R, Nierkens S, de Witte MA, et al. Association between anti-thymocyte globulin exposure and survival outcomes in adult unrelated haemopoietic cell transplantation: a multicentre, retrospective, pharmacodynamic cohort analysis. Lancet Haematol 2017; 4:e183.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Smith AR, Wagner JE. Alternative haematopoietic stem cell sources for transplantation: place of umbilical cord blood. Br J Haematol 2009; 147:246.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Navarrete C, Contreras M. Cord blood banking: a historical perspective. Br J Haematol 2009; 147:236.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Daikeler T, Labopin M, Ruggeri A, et al. New autoimmune diseases after cord blood transplantation: a retrospective study of EUROCORD and the Autoimmune Disease Working Party of the European Group for Blood and Marrow Transplantation. Blood 2013; 121:1059.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Broxmeyer HE, Douglas GW, Hangoc G, et al. Human umbilical cord blood as a potential source of transplantable hematopoietic stem/progenitor cells. Proc Natl Acad Sci U S A 1989; 86:3828.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Barker JN, Byam C, Scaradavou A. How I treat: the selection and acquisition of unrelated cord blood grafts. Blood 2011; 117:2332.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Stotler C, Bolwell B, Sobecks R, et al. Are backup BM harvests worthwhile in unrelated donor allogeneic transplants? Bone Marrow Transplant 2010; 45:49.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Rubinstein P, Carrier C, Scaradavou A, et al. Outcomes among 562 recipients of placental-blood transplants from unrelated donors. N Engl J Med 1998; 339:1565.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Barker JN, Scaradavou A, Stevens CE. Combined effect of total nucleated cell dose and HLA match on transplantation outcome in 1061 cord blood recipients with hematologic malignancies. Blood 2010; 115:1843.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lee SJ, Klein J, Haagenson M, et al. High-resolution donor-recipient HLA matching contributes to the success of unrelated donor marrow transplantation. Blood 2007; 110:4576.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           McCullough J, McKenna D, Kadidlo D, et al. Mislabeled units of umbilical cord blood detected by a quality assurance program at the transplantation center. Blood 2009; 114:1684.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Eapen M, Klein JP, Sanz GF, et al. Effect of donor-recipient HLA matching at HLA A, B, C, and DRB1 on outcomes after umbilical-cord blood transplantation for leukaemia and myelodysplastic syndrome: a retrospective analysis. Lancet Oncol 2011; 12:1214.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Eapen M, Rubinstein P, Zhang MJ, et al. Outcomes of transplantation of unrelated donor umbilical cord blood and bone marrow in children with acute leukaemia: a comparison study. Lancet 2007; 369:1947.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Eapen M, Rocha V, Sanz G, et al. Effect of graft source on unrelated donor haemopoietic stem-cell transplantation in adults with acute leukaemia: a retrospective analysis. Lancet Oncol 2010; 11:653.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Stevens CE, Carrier C, Carpenter C, et al. HLA mismatch direction in cord blood transplantation: impact on outcome and implications for cord blood unit selection. Blood 2011; 118:3969.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Cutler C, Kim HT, Sun L, et al. Donor-specific anti-HLA antibodies predict outcome in double umbilical cord blood transplantation. Blood 2011; 118:6691.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ruggeri A, Rocha V, Masson E, et al. Impact of donor-specific anti-HLA antibodies on graft failure and survival after reduced intensity conditioning-unrelated cord blood transplantation: a Eurocord, Société Francophone d'Histocompatibilité et d'Immunogénétique (SFHI) and Société Française de Greffe de Moelle et de Thérapie Cellulaire (SFGM-TC) analysis. Haematologica 2013; 98:1154.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Rocha V, Gluckman E, Eurocord-Netcord registry and European Blood and Marrow Transplant group. Improving outcomes of cord blood transplantation: HLA matching, cell dose and other graft- and transplantation-related factors. Br J Haematol 2009; 147:262.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Eapen M, Klein JP, Ruggeri A, et al. Impact of allele-level HLA matching on outcomes after myeloablative single unit umbilical cord blood transplantation for hematologic malignancy. Blood 2014; 123:133.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Sekine T, Marin D, Cao K, et al. Specific combinations of donor and recipient KIR-HLA genotypes predict for large differences in outcome after cord blood transplantation. Blood 2016; 128:297.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ciurea SO, Cao K, Fernandez-Vina M, et al. The European Society for Blood and Marrow Transplantation (EBMT) Consensus Guidelines for the Detection and Treatment of Donor-specific Anti-HLA Antibodies (DSA) in Haploidentical Hematopoietic Cell Transplantation. Bone Marrow Transplant 2018; 53:521.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Gluckman E, Rocha V, Boyer-Chammard A, et al. Outcome of cord-blood transplantation from related and unrelated donors. Eurocord Transplant Group and the European Blood and Marrow Transplantation Group. N Engl J Med 1997; 337:373.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Wagner JE, Barker JN, DeFor TE, et al. Transplantation of unrelated donor umbilical cord blood in 102 patients with malignant and nonmalignant diseases: influence of CD34 cell dose and HLA disparity on treatment-related mortality and survival. Blood 2002; 100:1611.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Migliaccio AR, Adamson JW, Stevens CE, et al. Cell dose and speed of engraftment in placental/umbilical cord blood transplantation: graft progenitor cell content is a better predictor than nucleated cell quantity. Blood 2000; 96:2717.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Yoo KH, Lee SH, Kim HJ, et al. The impact of post-thaw colony-forming units-granulocyte/macrophage on engraftment following unrelated cord blood transplantation in pediatric recipients. Bone Marrow Transplant 2007; 39:515.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Alonso JM 3rd, Regan DM, Johnson CE, et al. A simple and reliable procedure for cord blood banking, processing, and freezing: St Louis and Ohio Cord Blood Bank experiences. Cytotherapy 2001; 3:429.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Rocha V, Cornish J, Sievers EL, et al. Comparison of outcomes of unrelated bone marrow and umbilical cord blood transplants in children with acute leukemia. Blood 2001; 97:2962.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Gluckman E, Rocha V, Arcese W, et al. Factors associated with outcomes of unrelated cord blood transplant: guidelines for donor choice. Exp Hematol 2004; 32:397.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Rosenau EH, Sugrue MW, Haller M, et al. Characteristics of thawed autologous umbilical cord blood. Transfusion 2012; 52:2234.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Sideri A, Neokleous N, Brunet De La Grange P, et al. An overview of the progress on double umbilical cord blood transplantation. Haematologica 2011; 96:1213.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ruggeri A, Sanz G, Bittencourt H, et al. Comparison of outcomes after single or double cord blood transplantation in adults with acute leukemia using different types of myeloablative conditioning regimen, a retrospective study on behalf of Eurocord and the Acute Leukemia Working Party of EBMT. Leukemia 2014; 28:779.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Verneris MR, Brunstein CG, Barker J, et al. Relapse risk after umbilical cord blood transplantation: enhanced graft-versus-leukemia effect in recipients of 2 units. Blood 2009; 114:4293.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Wagner JE Jr, Eapen M, Carter S, et al. One-unit versus two-unit cord-blood transplantation for hematologic cancers. N Engl J Med 2014; 371:1685.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Barker JN, Weisdorf DJ, DeFor TE, et al. Transplantation of 2 partially HLA-matched umbilical cord blood units to enhance engraftment in adults with hematologic malignancy. Blood 2005; 105:1343.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Berglund S, Okas M, Gertow J, et al. Stable mixed donor-donor chimerism after double cord blood transplantation. Int J Hematol 2009; 90:526.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Michel G, Galambrun C, Sirvent A, et al. Single- vs double-unit cord blood transplantation for children and young adults with acute leukemia or myelodysplastic syndrome. Blood 2016; 127:3450.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Balligand L, Galambrun C, Sirvent A, et al. Single-Unit versus Double-Unit Umbilical Cord Blood Transplantation in Children and Young Adults with Residual Leukemic Disease. Biol Blood Marrow Transplant 2019; 25:734.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Labopin M, Ruggeri A, Gorin NC, et al. Cost-effectiveness and clinical outcomes of double versus single cord blood transplantation in adults with acute leukemia in France. Haematologica 2014; 99:535.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kindwall-Keller TL, Hegerfeldt Y, Meyerson HJ, et al. Prospective study of one- vs two-unit umbilical cord blood transplantation following reduced intensity conditioning in adults with hematological malignancies. Bone Marrow Transplant 2012; 47:924.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Zheng CC, Zhu XY, Tang BL, et al. Double vs. single cord blood transplantation in adolescent and adult hematological malignancies with heavier body weight (≥50 kg). Hematology 2018; 23:96.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Avery S, Shi W, Lubin M, et al. Influence of infused cell dose and HLA match on engraftment after double-unit cord blood allografts. Blood 2011; 117:3277.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Horwitz ME, Chao NJ, Rizzieri DA, et al. Umbilical cord blood expansion with nicotinamide provides long-term multilineage engraftment. J Clin Invest 2014; 124:3121.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Horwitz ME, Wease S, Blackwell B, et al. Phase I/II Study of Stem-Cell Transplantation Using a Single Cord Blood Unit Expanded Ex Vivo With Nicotinamide. J Clin Oncol 2019; 37:367.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Peled T, Shoham H, Aschengrau D, et al. Nicotinamide, a SIRT1 inhibitor, inhibits differentiation and facilitates expansion of hematopoietic progenitor cells with enhanced bone marrow homing and engraftment. Exp Hematol 2012; 40:342.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Horwitz ME, Stiff PJ, Cutler C, et al. Omidubicel vs standard myeloablative umbilical cord blood transplantation: results of a phase 3 randomized study. Blood 2021; 138:1429.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Anand S, Thomas S, Hyslop T, et al. Transplantation of Ex Vivo Expanded Umbilical Cord Blood (NiCord) Decreases Early Infection and Hospitalization. Biol Blood Marrow Transplant 2017; 23:1151.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           de Lima M, McNiece I, Robinson SN, et al. Cord-blood engraftment with ex vivo mesenchymal-cell coculture. N Engl J Med 2012; 367:2305.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Delaney C, Heimfeld S, Brashem-Stein C, et al. Notch-mediated expansion of human cord blood progenitor cells capable of rapid myeloid reconstitution. Nat Med 2010; 16:232.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Wagner JE Jr, Brunstein CG, Boitano AE, et al. Phase I/II Trial of StemRegenin-1 Expanded Umbilical Cord Blood Hematopoietic Stem Cells Supports Testing as a Stand-Alone Graft. Cell Stem Cell 2016; 18:144.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Boitano AE, Wang J, Romeo R, et al. Aryl hydrocarbon receptor antagonists promote the expansion of human hematopoietic stem cells. Science 2010; 329:1345.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Zhu X, Sun Q, Tan WS, Cai H. Reducing TGF-β1 cooperated with StemRegenin 1 promoted the expansion ex vivo of cord blood CD34+ cells by inhibiting AhR signalling. Cell Prolif 2021; 54:e12999.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Subramaniam A, Žemaitis K, Talkhoncheh MS, et al. Lysine-specific demethylase 1A restricts ex vivo propagation of human HSCs and is a target of UM171. Blood 2020; 136:2151.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Fernández MN. Improving the outcome of cord blood transplantation: use of mobilized HSC and other cells from third party donors. Br J Haematol 2009; 147:161.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Liu H, Rich ES, Godley L, et al. Reduced-intensity conditioning with combined haploidentical and cord blood transplantation results in rapid engraftment, low GVHD, and durable remissions. Blood 2011; 118:6438.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Milano F, Gooley T, Wood B, et al. Cord-Blood Transplantation in Patients with Minimal Residual Disease. N Engl J Med 2016; 375:944.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Brunstein CG, Gutman JA, Weisdorf DJ, et al. Allogeneic hematopoietic cell transplantation for hematologic malignancy: relative risks and benefits of double umbilical cord blood. Blood 2010; 116:4693.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Fuchs EJ, O'Donnell PV, Eapen M, et al. Double unrelated umbilical cord blood vs HLA-haploidentical bone marrow transplantation: the BMT CTN 1101 trial. Blood 2021; 137:420.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Brunstein CG, Fuchs EJ, Carter SL, et al. Alternative donor transplantation after reduced intensity conditioning: results of parallel phase 2 trials using partially HLA-mismatched related bone marrow or unrelated double umbilical cord blood grafts. Blood 2011; 118:282.
          </a>
         </li>
         <li class="breakAll">
          http://www.bmdw.org/ (Accessed on July 13, 2011).
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ballen K. Umbilical Cord Blood Transplantation: Challenges and Future Directions. Stem Cells Transl Med 2017; 6:1312.
          </a>
         </li>
        </ol>
       </div>
       <div id="topicVersionRevision">
        Topic 16563 Version 29.0
       </div>
      </div>
      <div class="row">
       <div class="col-12">
        <h4 style="text-align: center;padding: 20px;color: cadetblue;">
         References
        </h4>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/34724722" id="rid0" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          1 : Umbilical cord blood transplantation: Still growing and improving.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19796272" id="rid1" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          2 : Cord blood banking: 'providing cord blood banking for a nation'.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19796272" id="rid2" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          3 : Cord blood banking: 'providing cord blood banking for a nation'.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11880705" id="rid3" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          4 : Umbilical cord blood transplantation: current state of the art.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8429851" id="rid4" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          5 : Analysis of 462 transplantations from unrelated donors facilitated by the National Marrow Donor Program.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/3897863" id="rid5" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          6 : Marrow transplantation from related donors other than HLA-identical siblings.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11499955" id="rid6" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          7 : Results of unrelated umbilical cord blood hematopoietic stem cell transplant.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12064362" id="rid7" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          8 : Searching for unrelated donor hematopoietic stem cells: availability and speed of umbilical cord blood versus bone marrow.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10861319" id="rid8" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          9 : Graft-versus-host disease in children who have received a cord-blood or bone marrow transplant from an HLA-identical sibling. Eurocord and International Bone Marrow Transplant Registry Working Committee on Alternative Donor and Stem Cell Sources.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/27376453" id="rid9" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          10 : Clinical separation of cGvHD and GvL and better GvHD-free/relapse-free survival (GRFS) after unrelated cord blood transplantation for AML.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/32442301" id="rid10" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          11 : Adult cord blood transplant results in comparable overall survival and improved GRFS vs matched related transplant.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28499936" id="rid11" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          12 : Umbilical Cord Blood Transplantation without Antithymocyte Globulin Results in Similar Survival but Better Quality of Life Compared with Unrelated Peripheral Blood Stem Cell Transplantation for the Treatment of Acute Leukemia-A Retrospective Study in China.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18395491" id="rid12" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          13 : Umbilical cord blood transplantation: basic biology and clinical challenges to immune reconstitution.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19277981" id="rid13" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          14 : Differences amid bone marrow and cord blood hematopoietic stem/progenitor cell division kinetics.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15676210" id="rid14" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          15 : A multifactorial analysis of umbilical cord blood, adult bone marrow and mobilized peripheral blood progenitors using the improved ML-IC assay.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7500049" id="rid15" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          16 : Improved engraftment of human hematopoietic cells in severe combined immunodeficient (SCID) mice carrying human cytokine transgenes.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7513200" id="rid16" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          17 : Immature human cord blood progenitors engraft and proliferate to high levels in severe combined immunodeficient mice.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/31089283" id="rid17" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          18 : Cord blood research, banking, and transplantation: achievements, challenges, and perspectives.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19778207" id="rid18" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          19 : Biological differences between neonatal and adult human hematopoietic stem/progenitor cells.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19796270" id="rid19" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          20 : Cord blood transplantation for haematological malignancies: conditioning regimens, double cord transplant and infectious complications.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28330607" id="rid20" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          21 : Association between anti-thymocyte globulin exposure and survival outcomes in adult unrelated haemopoietic cell transplantation: a multicentre, retrospective, pharmacodynamic cohort analysis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19796274" id="rid21" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          22 : Alternative haematopoietic stem cell sources for transplantation: place of umbilical cord blood.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19796273" id="rid22" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          23 : Cord blood banking: a historical perspective.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23247725" id="rid23" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          24 : New autoimmune diseases after cord blood transplantation: a retrospective study of EUROCORD and the Autoimmune Disease Working Party of the European Group for Blood and Marrow Transplantation.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/2566997" id="rid24" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          25 : Human umbilical cord blood as a potential source of transplantable hematopoietic stem/progenitor cells.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21149636" id="rid25" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          26 : How I treat: the selection and acquisition of unrelated cord blood grafts.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19421170" id="rid26" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          27 : Are backup BM harvests worthwhile in unrelated donor allogeneic transplants?
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9828244" id="rid27" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          28 : Outcomes among 562 recipients of placental-blood transplants from unrelated donors.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20029048" id="rid28" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          29 : Combined effect of total nucleated cell dose and HLA match on transplantation outcome in 1061 cord blood recipients with hematologic malignancies.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17785583" id="rid29" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          30 : High-resolution donor-recipient HLA matching contributes to the success of unrelated donor marrow transplantation.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19487257" id="rid30" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          31 : Mislabeled units of umbilical cord blood detected by a quality assurance program at the transplantation center.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21982422" id="rid31" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          32 : Effect of donor-recipient HLA matching at HLA A, B, C, and DRB1 on outcomes after umbilical-cord blood transplantation for leukaemia and myelodysplastic syndrome: a retrospective analysis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17560447" id="rid32" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          33 : Outcomes of transplantation of unrelated donor umbilical cord blood and bone marrow in children with acute leukaemia: a comparison study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20558104" id="rid33" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          34 : Effect of graft source on unrelated donor haemopoietic stem-cell transplantation in adults with acute leukaemia: a retrospective analysis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21750317" id="rid34" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          35 : HLA mismatch direction in cord blood transplantation: impact on outcome and implications for cord blood unit selection.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21940825" id="rid35" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          36 : Donor-specific anti-HLA antibodies predict outcome in double umbilical cord blood transplantation.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23242594" id="rid36" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          37 : Impact of donor-specific anti-HLA antibodies on graft failure and survival after reduced intensity conditioning-unrelated cord blood transplantation: a Eurocord, SociétéFrancophone d'Histocompatibilitéet d'Immunogénétique (SFHI) and SociétéFrançaise de Greffe de Moelle et de Thérapie Cellulaire (SFGM-TC) analysis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19796275" id="rid37" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          38 : Improving outcomes of cord blood transplantation: HLA matching, cell dose and other graft- and transplantation-related factors.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24141369" id="rid38" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          39 : Impact of allele-level HLA matching on outcomes after myeloablative single unit umbilical cord blood transplantation for hematologic malignancy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/27247137" id="rid39" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          40 : Specific combinations of donor and recipient KIR-HLA genotypes predict for large differences in outcome after cord blood transplantation.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29335625" id="rid40" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          41 : The European Society for Blood and Marrow Transplantation (EBMT) Consensus Guidelines for the Detection and Treatment of Donor-specific Anti-HLA Antibodies (DSA) in Haploidentical Hematopoietic Cell Transplantation.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9241126" id="rid41" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          42 : Outcome of cord-blood transplantation from related and unrelated donors. Eurocord Transplant Group and the European Blood and Marrow Transplantation Group.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12176879" id="rid42" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          43 : Transplantation of unrelated donor umbilical cord blood in 102 patients with malignant and nonmalignant diseases: influence of CD34 cell dose and HLA disparity on treatment-related mortality and survival.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11023503" id="rid43" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          44 : Cell dose and speed of engraftment in placental/umbilical cord blood transplantation: graft progenitor cell content is a better predictor than nucleated cell quantity.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17334379" id="rid44" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          45 : The impact of post-thaw colony-forming units-granulocyte/macrophage on engraftment following unrelated cord blood transplantation in pediatric recipients.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11953027" id="rid45" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          46 : A simple and reliable procedure for cord blood banking, processing, and freezing: St Louis and Ohio Cord Blood Bank experiences.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11342418" id="rid46" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          47 : Comparison of outcomes of unrelated bone marrow and umbilical cord blood transplants in children with acute leukemia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15050751" id="rid47" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          48 : Factors associated with outcomes of unrelated cord blood transplant: guidelines for donor choice.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22321210" id="rid48" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          49 : Characteristics of thawed autologous umbilical cord blood.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21546497" id="rid49" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          50 : An overview of the progress on double umbilical cord blood transplantation.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24005245" id="rid50" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          51 : Comparison of outcomes after single or double cord blood transplantation in adults with acute leukemia using different types of myeloablative conditioning regimen, a retrospective study on behalf of Eurocord and the Acute Leukemia Working Party of EBMT.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19706886" id="rid51" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          52 : Relapse risk after umbilical cord blood transplantation: enhanced graft-versus-leukemia effect in recipients of 2 units.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25354103" id="rid52" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          53 : One-unit versus two-unit cord-blood transplantation for hematologic cancers.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15466923" id="rid53" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          54 : Transplantation of 2 partially HLA-matched umbilical cord blood units to enhance engraftment in adults with hematologic malignancy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19697099" id="rid54" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          55 : Stable mixed donor-donor chimerism after double cord blood transplantation.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/27099151" id="rid55" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          56 : Single- vs double-unit cord blood transplantation for children and young adults with acute leukemia or myelodysplastic syndrome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/30385256" id="rid56" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          57 : Single-Unit versus Double-Unit Umbilical Cord Blood Transplantation in Children and Young Adults with Residual Leukemic Disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24143000" id="rid57" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          58 : Cost-effectiveness and clinical outcomes of double versus single cord blood transplantation in adults with acute leukemia in France.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22002488" id="rid58" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          59 : Prospective study of one- vs two-unit umbilical cord blood transplantation following reduced intensity conditioning in adults with hematological malignancies.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28795658" id="rid59" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          60 : Double vs. single cord blood transplantation in adolescent and adult hematological malignancies with heavier body weight (≥50 kg).
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21149633" id="rid60" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          61 : Influence of infused cell dose and HLA match on engraftment after double-unit cord blood allografts.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24911148" id="rid61" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          62 : Umbilical cord blood expansion with nicotinamide provides long-term multilineage engraftment.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/30523748" id="rid62" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          63 : Phase I/II Study of Stem-Cell Transplantation Using a Single Cord Blood Unit Expanded Ex Vivo With Nicotinamide.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22198152" id="rid63" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          64 : Nicotinamide, a SIRT1 inhibitor, inhibits differentiation and facilitates expansion of hematopoietic progenitor cells with enhanced bone marrow homing and engraftment.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/34157093" id="rid64" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          65 : Omidubicel vs standard myeloablative umbilical cord blood transplantation: results of a phase 3 randomized study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28392378" id="rid65" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          66 : Transplantation of Ex Vivo Expanded Umbilical Cord Blood (NiCord) Decreases Early Infection and Hospitalization.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23234514" id="rid66" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          67 : Cord-blood engraftment with ex vivo mesenchymal-cell coculture.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20081862" id="rid67" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          68 : Notch-mediated expansion of human cord blood progenitor cells capable of rapid myeloid reconstitution.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26669897" id="rid68" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          69 : Phase I/II Trial of StemRegenin-1 Expanded Umbilical Cord Blood Hematopoietic Stem Cells Supports Testing as a Stand-Alone Graft.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20688981" id="rid69" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          70 : Aryl hydrocarbon receptor antagonists promote the expansion of human hematopoietic stem cells.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/33522060" id="rid70" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          71 : Reducing TGF-β1 cooperated with StemRegenin 1 promoted the expansion ex vivo of cord blood CD34+ cells by inhibiting AhR signalling.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/32582923" id="rid71" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          72 : Lysine-specific demethylase 1A restricts ex vivo propagation of human HSCs and is a target of UM171.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19796265" id="rid72" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          73 : Improving the outcome of cord blood transplantation: use of mobilized HSC and other cells from third party donors.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21976674" id="rid73" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          74 : Reduced-intensity conditioning with combined haploidentical and cord blood transplantation results in rapid engraftment, low GVHD, and durable remissions.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/27602666" id="rid74" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          75 : Cord-Blood Transplantation in Patients with Minimal Residual Disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20686119" id="rid75" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          76 : Allogeneic hematopoietic cell transplantation for hematologic malignancy: relative risks and benefits of double umbilical cord blood.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/33475736" id="rid76" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          77 : Double unrelated umbilical cord blood vs HLA-haploidentical bone marrow transplantation: the BMT CTN 1101 trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21527516" id="rid77" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          78 : Alternative donor transplantation after reduced intensity conditioning: results of parallel phase 2 trials using partially HLA-mismatched related bone marrow or unrelated double umbilical cord blood grafts.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21527516" id="rid78" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          79 : Alternative donor transplantation after reduced intensity conditioning: results of parallel phase 2 trials using partially HLA-mismatched related bone marrow or unrelated double umbilical cord blood grafts.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28456009" id="rid79" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          80 : Umbilical Cord Blood Transplantation: Challenges and Future Directions.
         </p>
        </a>
       </div>
      </div>
     </div>
    </div>
   </section>
  </section>
  <!-- End Main Menu Area -->
  <!-- Start Search Popup Area -->
  <!-- End Footer Area -->
  <!-- Back to top -->
  <a class="scrolltop" href="#top">
   <i class="icofont-hand-drawn-up">
   </i>
  </a>
  <!-- End Back to top -->
  <!-- jQuery Min JS -->
  <!-- Prpper JS -->
  <!-- Bootstrap Min JS -->
  <!-- Classy Nav Min Js -->
  <!-- Owl Carousel Min Js -->
  <!-- Magnific Popup JS -->
  <!-- CounterUp JS -->
  <!-- Waypoints JS -->
  <!-- Form Validator Min JS -->
  <!-- Contact Form Min JS -->
  <!-- Main JS -->
  <!-- Global site tag (gtag.js) - Google Analytics -->
 </body>
</html>
